Related Experiment Video

Updated: May 25, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Optimizing the use of epidermal growth factor receptor inhibitors in advanced non-small-lung cancer (NSCLC)

Emad Shash1, Fedro Alessandro Peccatori, Hatem A Azim

  • 1Department of Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt;

Journal of Thoracic Disease
|January 21, 2012
PubMed

Insights

Lung cancer treatment is improving with targeted therapies like epidermal growth factor receptor (EGFR) inhibitors. Biomarkers are crucial for selecting patients who will benefit most from these expensive, advanced lung cancer drugs.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Lung cancer is a leading cause of cancer death in the US and Europe.
  • Platinum-based chemotherapy offers modest survival benefits and impacts quality of life.
  • Targeted therapies, particularly epidermal growth factor receptor (EGFR) inhibitors, show promise in advanced non-small cell lung cancer (NSCLC).

Purpose of the Study:

  • To review recent advancements in EGFR inhibitors for advanced NSCLC treatment.
  • To discuss the role of predictive biomarkers in patient selection for EGFR inhibitor therapy.

Main Methods:

  • Literature review of recent studies on EGFR inhibitors and predictive biomarkers in NSCLC.
  • Analysis of clinical trial data and research findings.

Main Results:

  • EGFR inhibitors demonstrate significant clinical activity in both first-line and salvage settings for NSCLC.
  • Patient response to EGFR inhibitors varies, highlighting the need for predictive biomarkers.
  • Several predictive biomarkers have been developed to identify patients likely to benefit from these targeted agents.

Conclusions:

  • EGFR inhibitors represent a significant advancement in advanced NSCLC treatment.
  • Predictive biomarkers are essential for optimizing patient selection and maximizing the benefit of costly EGFR inhibitors.
  • Further research into predictive biomarkers will improve personalized treatment strategies for lung cancer.
Keywords:
EGFRadvanced NSCLCbiomarkerscetuximaberlotinibgefitinib

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...